This document provides a short summary of this study for a general audience. You can
find more information in the scientific summary of the study. A link to the summary is
provided at the end of this document.
Study names
Short Title: A study to assess how well botulinum toxin type A works and how safe it is
in patients with post-stroke upper limb spasticity.
Full Scientific Title: A phase III study (a placebo-controlled, randomised, double-blind
comparative study and an open-label uncontrolled study) to evaluate the efficacy and
safety of GSK1358820 (botulinum toxin type A) in patients with post-stroke upper limb
spasticity.
Study Number: 207660
Who sponsored this study?
GlaxoSmithKline (GSK)
GSK Clinical Support Help Desk
Website: clinicalsupporthd.gsk.com/contact.html
Email: GSKClinicalSupportHD@gsk.com
General information about the clinical study
When and where was this study done?
The study started in August 2017 and ended in January 2019. All study sites were in
Japan.
What was the main reason for this study?
A stroke occurs when the blood (and oxygen) supply to the brain is blocked or reduced.
Patients who have had a stroke can experience muscle weakness and/or loss of muscle
function, including spasticity. Symptoms of spasticity include: stiffness or tightness in
the muscles and/or occasional uncontrolled twitching or movement (spasm).
Use of the data and information contained in this Document is unrestricted, provided that it may not
be used in applications by others for regulatory approval of a product. While not required, when using
these data, we ask that proper credit or attribution of GSK as the source of the data be given. GSK
disclaims liability for all uses of the data by users of this Document, to the fullest extent permitted by
applicable law. No trademark, patent, or regulatory/data exclusivity rights held by GSK are waived,
licensed or otherwise affected.